68.59
-0.07 (-0.10%)
| Previous Close | 68.66 |
| Volume | 23,876 |
| Price / Sales | 110.67 |
| Price / Book | 4.63 |
| 52 Weeks Range |
| Profit Margin | -107.77% |
| Operating Margin (TTM) | -879.63% |
| Diluted EPS (TTM) | -4.70 |
| Quarterly Revenue Growth (YOY) | 121.20% |
| Total Debt/Equity (MRQ) | 5.84% |
| Current Ratio (MRQ) | 5.12 |
| Operating Cash Flow (TTM) | -13.89 M |
| Levered Free Cash Flow (TTM) | -9.91 M |
| Return on Assets (TTM) | -26.82% |
| Return on Equity (TTM) | -49.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Sol-Gel Technologies Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | -0.3 |
| AI Insight | NA |
| Weighted Average | 0.44 |
Select this tab to load the latest available analysis.
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 70.00% |
| % Held by Institutions | 24.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Navellier & Associates Inc | 30 Jun 2026 | 5,785 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |